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Systematic reviews with network meta-analysis (NMA)
are published with increasing frequency in the health
care literature. Prior to 2008, very few systematic reviews
contained a NMA [1]; however, there has been a marked
increase, to mid-2012 Lee recorded 201 published net-
works [2]. The statistical method has been available since
2002 [3,4] and owes its origins to much earlier work [5,6].
NMA has matured and models are available for all types
of underlying data and summary effect measures [7-12]
and can be readily implemented in both frequentist and
Bayesian frameworks with pre-written programmes avail-
able in widely used softwares [8,13-15].
Recently, focus has shifted to making NMA more ac-
cessible [16,17]; however, the conduct of systematic re-
views for NMA has received less attention [18]. In this
special thematic series on network meta-analysis, the ed-
itors of Systematic Reviews are encouraging submissions
of methodological papers concerning the conduct and
reporting of meta-analyses and results papers (http://www.
systematicreviewsjournal.com/about/update/SysRevCFP).
As a preface to the series, this editorial provides an over-
view of the basic principles of NMA and summarises some
of the key challenges for those conducting a systematic
review.The need for network meta-analysis in comparative
effectiveness research
Why has NMA increased in popularity? To illustrate,
consider the relative effectiveness of six psychotherapies
vs. treatment as usual for treatment of moderate to severe
depression [19]. In a pairwise meta-analysis, the systematic
reviewer has three synthesis options: (1) “lump” all six
psychotherapies together to form a single comparator,
(2) conduct six separate pairwise meta-analyses in a single
systematic review, or (3) conduct six separate systematic
reviews. If the question of interest to the decision-maker isCorrespondence: d.m.caldwell@bristol.ac.uk
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unless otherwise stated.“which psychotherapy should I recommend for depression?”
the results of pairwise syntheses do not satisfactorily
translate into practice. A clinician does not recommend
an “average” psychotherapy to a patient but a specific one,
such as cognitive behavioural therapy. To use results from
options 2 and 3, the decision-maker must summarise
across multiple analyses/reviews without formal assess-
ment of whether the body evidence was coherent or simi-
lar enough to form a treatment recommendation. Such an
approach makes effect estimates problematic to interpret
and is not recommended [20].
NMA came to prominence within this decision-making
context [21,22]. NMA is the simultaneous comparison of
multiple competing treatments in a single statistical model
[23]. In its simplest form, it is the combination of direct
and indirect estimates of relative treatment effect, where
indirect evidence refers to evidence on treatment C rela-
tive to B obtained from A vs. B and A vs. C studies. This
is commonly depicted by the equation θIBC ¼ θDAC−θDAB
where θ denotes the true underlying treatment effect esti-
mate (e.g. log odds ratio, mean difference, etc.) and the
superscript either Direct or Indirect evidence. If both direct
and indirect estimates are available, they can be pooled to
produce an internally coherent set of effect estimates of
each treatment relative to every other whether or not they
have been compared in head-to-head trials. It is also pos-
sible to calculate the probability of one treatment being the
best for a specific outcome. Treatment options can then be
ranked from the best to the worst for each outcome.Systematic review process for a network meta-analysis
The rigorous conduct of a standard systematic review
should apply equally to a NMA. For example, it is good
practice to register a protocol for NMA on a repository
such as PROSPERO [24] and report a thorough and re-
producible literature search. Inclusion/exclusion criteria
for a NMA should also be based on a well-defined popu-
lation, intervention, comparator, outcome (PICO) research
question, since it is the specification of the PICO which
ensures the key assumption of transitivity is fulfilled.This is an Open Access article distributed under the terms of the Creative
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appears in the A vs. B and A vs. C studies [25]. Transitivity
can be examined by comparing the distribution of poten-
tial effect modifiers across the different comparisons [26],
since if there is an imbalance in the presence of effect
modifiers across the A vs. B and A vs. C comparisons, the
conclusions about B vs. C may be in doubt. Potential effect
modifiers should be pre-specified in a protocol and are
usually study level characteristics which are routinely ex-
tracted in systematic reviews, such as age, severity, dose,
setting, etc. Identifying a lack of transitivity may be dif-
ficult and sufficient detail is not always available in
published trials to allow a thorough assessment [27,28].
The statistical manifestation of the transitivity assump-
tion is called consistency, which holds when the direct
and indirect sources of evidence are in agreement, i.e.
θ^ IBC ¼ θ^DAC−θ^DAB where ^ denotes observed estimates.
Transitivity should always be examined in NMA; how-
ever, it is only possible to assess consistency when there
are direct and indirect sources of evidence for a treat-
ment contrast. Thus, inconsistency is a property of “loops”
of evidence, here the loop A-B-C [29]. Empirical studies
have reported the frequency of statistically significant in-
consistency ranging from 2% to 14% of published “loops”
of evidence [9,30]. It has been argued, however, that the
detection of inconsistency in these studies may reveal less
about the reliability of NMA and rather more about the
problems associated with systematic review options 2 and
3 identified above [31]. Thus, the assessment of transitivity
is of fundamental importance in the conduct of the sys-
tematic review.Defining treatments and network size in NMA
Perhaps the biggest deviation from a pairwise systematic
review is in the definition of treatments in the network.
The identity of each distinct treatment can be preserved
in NMA; there is no need to lump across doses or ignore
co-treatments in order to conduct analysis. Indeed, the
statistical inconsistency noted in empirical studies can
often be explained by separating treatments into dis-
tinct doses or co-treatments [32].
Treatments included in the network can be divided
into a decision and supplementary set. Treatments within
the decision set are the focal treatments of interest to sys-
tematic review authors. However, a supplementary set of
treatments may also be incorporated into the network to
provide additional evidence on relative treatment effects
of the decision set. For example, a placebo comparator is
rarely of practical clinical interest but its inclusion might
(i) connect an otherwise unconnected network of treat-
ments, (ii) increase the precision of the treatment effect
estimates of interest if the bulk of the evidence is on pla-
cebo comparisons, or (iii) improve estimates of between-trial heterogeneity. Care must be taken to ensure that all
treatments in the network are “jointly randomizable” [25].
That is, all treatments should be options for the popula-
tion considered in the systematic review such that they
could reasonably be compared in a single trial.
Sturtz and Bender [33] have referred to network size
as an “unsolved issue” in NMA, and it is an area of de-
veloping interest [34,35]. The inclusion or exclusion of
treatments from the network has the potential to modify
treatment effect estimates and the treatment rankings
[36]. A meticulous PICO and pre-specified strategy for
extending the network [37] will mitigate but not elimin-
ate the risk of post hoc inclusion/exclusion of treatments.
Where unexpected interventions are identified by the lit-
erature search, a sensitivity analysis should be undertaken
to examine the impact of its inclusion/exclusion. For the
systematic reviewer, the most important consideration in
determining network size is likely to be the resource im-
plications of including additional treatments or searching
for further evidence to connect existing networks. For
example, although a search strategy for decision set treat-
ments is also likely to return those studies also including a
supplementary set comparator, the additional resource
employed in title screening and eligibility checking is not
inconsequential. The larger the network the more inten-
sive the assessment of transitivity, data extraction, risk of
bias assessment and tabulation of results is likely to be.
Assuming the transitivity assumption holds, the systematic
reviewer must balance this extra resource against the
benefit of increasing network size.
Summarising and reporting network meta-analysis
An important source of guidance for systematic reviewers
is the Cochrane Collaborations’ Comparing Multiple In-
terventions Methods Group. The group focuses on meth-
odology for comparing multiple interventions in Cochrane
Intervention Reviews; however, much of the work is
generalizable. An example protocol for reviews containing
a NMA is available, as is guidance on statistical methods
and interpretation and presentation of results (see http://
cmimg.cochrane.org/comparing-multiple-interventions-
cochrane-reviews). Presenting the results from a system-
atic review with NMA can be challenging [38,39]. The
number of treatments included in NMA can be large;
Veroniki’s [9] findings are representative with a range of 4
to 17 treatments (median 6). The number of pairwise com-
parisons to report from 4 treatments is 6; from 17 treat-
ments, it is 136.
It is commonplace in pairwise systematic reviews to
consider the quality of the body of evidence and to sum-
marise the confidence one can place in the conclusions.
Attention is turning to how approaches, such as GRADE,
can be extended to NMA [40,41]. There are no universally
accepted standards for reporting either the methods or
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http://www.systematicreviewsjournal.com/content/3/1/109results of a NMA, although there are a number of society
and national technology assessment organisations who
have produced in-house guidance [42,43]. Finally, journal
editors and peer reviewers should be mindful that web ap-
pendices and supplementary files are a necessity in NMA
and they can be large. International initiatives such as the
forthcoming extension to PRISMA for reporting of NMA
will provide systematic reviewers the much needed guid-
ance here [44].
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